Compare BOKF & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOKF | KYMR |
|---|---|---|
| Founded | 1910 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.8B |
| IPO Year | 2007 | 2020 |
| Metric | BOKF | KYMR |
|---|---|---|
| Price | $127.55 | $77.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 26 |
| Target Price | ★ $127.10 | $107.72 |
| AVG Volume (30 Days) | 295.9K | ★ 622.7K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 12.65 | N/A |
| EPS | ★ 9.17 | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $6.56 | $16.05 |
| Revenue Next Year | $5.35 | $4.79 |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $85.08 | $19.45 |
| 52 Week High | $138.42 | $103.00 |
| Indicator | BOKF | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 40.07 |
| Support Level | $121.15 | $64.95 |
| Resistance Level | $138.25 | $77.93 |
| Average True Range (ATR) | 2.90 | 3.77 |
| MACD | -0.00 | -1.05 |
| Stochastic Oscillator | 62.91 | 11.57 |
BOK Financial Corp is a financial institution based in Oklahoma that offers a broad range of nationally competitive financial products and services. The company operates through three main segments: Commercial Banking, Consumer Banking, and Wealth Management. Commercial Banking provides lending, treasury and cash management, and risk management services, and includes the TransFund EFT network. Consumer Banking focuses on retail lending, deposit services, and mortgage loan origination and servicing. Wealth Management engages mainly in brokerage and trading activities, particularly in U.S. government agency mortgage-backed securities and related derivatives. The company generates the majority of its revenue from the Commercial Banking segment.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.